CAPTRUST Financial Advisors
DNTH icon

CAPTRUST Financial Advisors’s Dianthus Therapeutics DNTH Stock Holding History

CAPTRUST Financial Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14
Closed -$1K – 4970
2022
Q1 		$1K Hold
14
– – ﹤0.01% 4678
2021
Q4 		$1K Sell
14
-250
-95% -$25.1K ﹤0.01% 4555
2021
Q3 		$31K Hold
264
– – ﹤0.01% 2878
2021
Q2 		$41K Buy
264
+14
+6% +$2.57K ﹤0.01% 2635
2021
Q1 		$47K Hold
250
– – ﹤0.01% 2461
2020
Q4 		$31K Hold
250
– – ﹤0.01% 2051
2020
Q3 		$28K Hold
250
– – ﹤0.01% 1834
2020
Q2 		$30K Buy
+250
New +$35.2K ﹤0.01% 1796

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CAPTRUST Financial Advisors's DNTH Position: Q2 2022 in Review

CAPTRUST Financial Advisors sold out of Dianthus Therapeutics (DNTH) in Q2 2022, closing a stake of 14 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in DNTH in Q2 2020 and held it in 8 quarters. The position peaked at $47K in Q1 2021. 75 funds tracked by Wall St. Rank hold DNTH as of Q2 2022.

  • CAPTRUST Financial Advisors reported no remaining Dianthus Therapeutics position as of Q2 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 14 Dianthus Therapeutics shares in Q2 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Dianthus Therapeutics in Q2 2020 and held it in 8 quarters.
  • CAPTRUST Financial Advisors's Dianthus Therapeutics position peaked at $47K in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2022, filed 16 Aug 2022.